z-logo
open-access-imgOpen Access
Cognitive decline with chronic meningitis secondary to a COX-2 inhibitor
Author(s) -
David Ashton,
Peter Kim,
N. W. Griffiths,
Roy G. Beran
Publication year - 2004
Publication title -
age and ageing
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.014
H-Index - 143
eISSN - 1468-2834
pISSN - 0002-0729
DOI - 10.1093/ageing/afh112
Subject(s) - medicine , aseptic meningitis , cognitive decline , rofecoxib , lumbar puncture , lymphocytic pleocytosis , meningitis , incidence (geometry) , pediatrics , disease , dementia , immunology , encephalitis , cerebrospinal fluid , biochemistry , chemistry , virus , physics , optics , cyclooxygenase , enzyme
Non-steroidal anti-inflammatory drugs are currently being investigated as agents to reduce the incidence and progression of Alzheimer's disease. Paradoxically they have also been reported to induce deleterious effects on the central nervous system, including aseptic meningitis and cognitive decline in the elderly. We report a case of a 72-year-old woman who presented with a 6-week history of profound confusion whilst being treated with rofecoxib, a COX-2 inhibitor. Lumbar puncture demonstrated a lymphocytic pleocytosis with increased protein and normal glucose. Complete clinical remission occurred 5 days after the rofecoxib was ceased with no other cause found despite extensive investigation. This case illustrates that non-steroidal anti-inflammatory drugs, including the new COX-2 inhibitors, can produce chronic lymphocytic meningitis, which may manifest as cognitive decline. This mechanism may account for other case reports and epidemiological evidence of the association between non-steroidal anti-inflammatory drugs and confusion.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom